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We describe the anaerobic conversion of inositol stereoisomers to propionate and acetate by
the abundant intestinal genus Anaerostipes. A inositol pathway was elucidated by nuclear
magnetic resonance using [13C]-inositols, mass spectrometry and proteogenomic analyses in
A. rhamnosivorans, identifying 3-oxoacid CoA transferase as a key enzyme involved in both 3-
oxopropionyl-CoA and propionate formation. This pathway also allowed conversion of
phytate-derived inositol into propionate as shown with [13C]-phytate in fecal samples
amended with A. rhamnosivorans. Metabolic and (meta)genomic analyses explained the
adaptation of Anaerostipes spp. to inositol-containing substrates and identified a propionate-
production gene cluster to be inversely associated with metabolic biomarkers in (pre)dia-
betes cohorts. Co-administration of myo-inositol with live A. rhamnosivorans in western-diet
fed mice reduced fasting-glucose levels comparing to heat-killed A. rhamnosivorans after 6-
weeks treatment. Altogether, these data suggest a potential beneficial role for intestinal
Anaerostipes spp. in promoting host health.
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M icrobes inhabiting the human intestinal tract form alarge and dynamic microbial community that infersimportant health benefits to the host1. One of the major
functions of the intestinal microbes is the biosynthesis of
absorbable metabolites conferring effects on intestinal epithelia
and beyond2. Most studied are the short chain fatty acids
(SCFAs) that are known to signal to various G-protein coupled
receptors, have epigenetic effects and provide both metabolic and
immune signalling3,4. Acetate is the most abundant faecal SCFA
and has been suggested to affect body weight control, insulin
sensitivity and control of appetite5,6. Propionate and butyrate are
the main other SCFAs and not only signal to various receptors
but also have epigenetic effects by inhibiting histone deacetylase
activity7. Studies in human and model animals showed propio-
nate to decrease liver lipogenesis, hepatic and serum cholesterol
levels8, to reduce satiety9,10, and to induce apoptosis11,12. Three
propionate synthesis pathways have been identified in human
intestinal microbes, including the succinate, propanediol and
acrylate pathways13. Among these, the succinate pathway
appeared as the most abundant route and has been mainly
observed to operate in Bacteroidetes, Negativicutes and Verru-
comicrobia. The propanediol pathway was found to be widely
spread within intestinal anaerobes, including some abundant
bacteria such as Ruminococcus obeum (now Blautia obeum) and
Eubacterium hallii (now known as Anaerobutyricum spp)14,15.
The acrylate pathway was the least abundant with limited dis-
tribution in the gut community, including Coprococcus catus and
Megasphaera elsdenii13.
Butyrate is another important SCFA that is vital to maintain
healthy intestinal barrier functions16. Increasing evidence reveals
a strong inverse relation between butyrate-producing bacteria and
potential pathogenesis17–19. Butyrate-producing bacteria mainly
belong to two families Ruminococcaceae and Lachnospiraceae.
The genus Anaerostipes is also among the 15 most abundant taxa
and butyrogenic groups in a healthy microbiome20 and its species
are among the most efficient lactate consumers in the human
colon21. In addition, it has been reported that the abundance of
Anaerostipes was significantly decreased in type 2 diabetes sub-
jects from African and European origin22,23. Several studies have
shown that bacteria of this genus are capable of interacting with
other microbes with diverse catabolic capacities that produce
lactate24–26. There are presently four known Anaerostipes species,
including A. caccae, A. rhamnosivorans, A. hadrus and A.
butyraticus27–30. The species of this genus are not only able to use
a broad range of carbohydrates but also lactate plus acetate for
butyrogenesis. Whereas A. hadrus can use only D-lactate, A.
caccae and A. rhamnosivorans are able to use both the D- and L-
lactate stereoisomers, that are widely produced in the human
intestinal tract and accumulated in patients with gastrointestinal
disorders31. A. rhamnosivorans is among the most versatile spe-
cies within the genus and the only one having the capability of
fermenting dietary rhamnose to butyrate.
Inositol is a six-carbon cyclitol that is naturally present in a
variety of stereoisomers. The best studied isomer is myo-inositol
that is most abundantly present in the brain and other mam-
malian tissues32 as well as many foods and fruits in particular33.
Myo-inositol is involved in a large number of cellular functions,
including development and function of peripheral nerves,
osteogenesis and reproduction34. In recent years, several studies
have suggested that orally administered myo-inositol and its
isomer chiro-inositol can facilitate insulin signalling, improve
insulin sensitivity and reduce blood glucose concentration in
human disorders associated with insulin resistance, including
type 2 diabetes, polycystic ovary syndrome and gestational
diabetes34–37. It has been proposed that myo-inositol functions as
an insulin-sensitising substance by acting on insulin receptors so
that insulin can bind effectively, thus reducing insulin
resistance34. However, the exact mechanism by which myo-ino-
sitol or other inositol stereoisomers exert potential beneficial
effects is not known. Intriguingly, myo-inositol can be released
from dietary phytate by bacterial phytase activity in the colon38. It
has been shown that phytate supplementation in a rat model
increased propionate production in the stool after 3-week
intervention39 and a phytate-derived metabolite from the
microbial conversion has shown to promote HDAC3 activity in
the gut40. In addition, phytate is abundantly present the vege-
tarian diet that has been reported to increase among others the
abundance of Anaerostipes spp.41. Till date, only a few bacteria
have been shown to have capabilities of metabolising myo-ino-
sitol. Myo-inositol fermentation was first reported in Aerobacter
aerogenes, producing ethanol, CO2, acetic acid and succinic acid
as major end products42 and the degradation pathway was
reported via the keto-inositol43. More recently, Bacillus subtilis
was found to convert myo-inositol to dihydroxyacetone phos-
phate, acetyl-CoA and CO2 as metabolites from inositol44 while
Lactobacillus casei BL23 only metabolised myo-inositol under
aerobic conditions to produce dihydroxyacetone-phosphate,
acetaldehyde, acetyl-CoA and CO245. The myo-inositol cascade
till to dihydroxyacetone has been described previously and the
enzymes involved in this part of the pathway have been bio-
chemically and genetically characterised in Lactobacillus casei45
and Bacillus subtilis, where these are annotated as products of the
iolABCDEFGHIJ operon44. However, these bacteria all degrade
myo-inositol under aerobic conditions and are not naturally
found in the human intestine. In this study we report a pathway
involved in the conversion of myo-inositol or chiro-inositol to
propionate and acetate that was present in many but not all tested
strains of Anaerostipes spp. This unique pathway was further
elucidated using 13C-labelled inositol isotopomers and nuclear
magnetic resonance (NMR), mass spectrometry and proteoge-
nomic analyses in A. rhamnosivorans revealing a set of enzymes
involved in intestinal propionate formation that were only found
to be encoded in the genomes of Anaerostipes and related species.
Metagenomic analysis of the gut microbiota in prediabetes/dia-
betes cohorts showed a significant correlation of the propionate
pathway genes with biomarkers of insulin sensitivity. This was in
line with the observed reduction of fasting glucose in mice fed a
western diet and treated with live A. rhamnosivorans in the
presence of myo-inositol. Altogether this study provides the
molecular details of the conversion of dietary inositol stereo-
isomers into propionate and acetate by an abundant human
intestinal commensal, which is part of a phytate food chain in the
gut and further studies in human are needed to investigate the
potential use of Anaerostipes spp. to improve host health.
Results
Inositol fermentation by Anaerostipes species. Anaerostipes is
most known for its capability of producing butyrate from sugars
as well as lactate and acetate46. Interestingly, we found several
Anaerostipes strains to be able to utilise myo-inositol to produce
mainly equal amounts of propionate and acetate and minor
amounts of formate, hydrogen, lactate and butyrate (Fig. 1b)
while in absence of inositol no products were detected by any of
the strains (Supplementary Fig. 1). Both A. rhamnosivorans
DSM26241T and A. caccae DSM14662T metabolised inositol
rapidly (both with doubling times of 1.7 h) while strain A. hadrus
PEL85 showed some adaptation and grew somewhat slower
(doubling time 3.4 h) (Fig. 1a). All three Anaerostipes strains
completely consumed 15 mM myo-inositol after 33 h (Fig. 1b). In
contrast, A. hadrus DSM3319T, A. hadrus DSM108065 and A.
butyraticus DSM22094T did not ferment myo-inositol, even not
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after prolonged incubation times. A small amount of butyrate
(<1.5 mM) was produced by all myo-inositol degraders and non-
degraders, suggesting that this was likely a fermentation product
of the yeast extract and peptone present in the medium or a
carry-over carbon source from the inoculum. Of note, A. caccae
DSM14662T first produced lactate and subsequently metabolised
this and simultaneously produced butyrate, indicating that
butyrate formation was mostly from lactate (Fig. 1b). A. rham-
nosivorans DSM26241T and A. hadrus PEL85 performed a similar
conversion inside the cells that resulted in little accumulation of
lactate during growth (Fig. 1). Based on the observed stoichio-
metry of myo-inositol conversion to propionate and acetate, we
propose the theory fermentative equation as: 2C6H12O6 →
2C3H6O2+ 2C2H4O2+ CO2+H2+ CH2O2. Of note, the pro-
duction of CO2 was not determined due to the pre-existing
bicarbonate in the medium, however CO2 was clearly detected by
NMR analysis in the following section. In addition, we did not
observe any influence of additional acetate on propionate for-
mation (Supplementary Fig. 2).
Elucidation of myo-inositol fermentation pathway using 13C-
NMR and mass spectrometry. To elucidate the myo-inositol
pathway at the molecular level we used A. rhamnosivorans
DSM26241T as a model because of its rapid growth and used 13C-
labelled substrates in whole-cell NMR analysis. A. rhamnosivor-
ans was grown in bicarbonate-buffered medium containing either
[13C6]myo-inositol, [4-13C]myo-inositol or [4,5-13C2]myo-inosi-
tol as the energy and carbon source. The supernatants were
collected during the growth and analysed by NMR. Growth of A.
Fig. 1 Metabolite production from myo-inositol by Anaerostipes strains. The growth was performed in bicarbonate-buffered medium supplemented up to
15 mM myo-inositol as substrate. a Growth curves (n= 3 biological replicates); b Metabolite production and substrate consumption by 6 Anaerostipes
strains (n= 3 biological replicates). Data are presented as mean values ±SD.
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rhamnosivorans on [4,5-13C2]myo-inositol resulted in its com-
plete conversion into [3-13C]propionate as major end product
and minor amounts of [13C]CO2, [1-13C]ethanol, [2-13C]acetate,
[1-13C]acetate, [13C]formate after 8 h incubation (Fig. 2a, b). As
only single peaks were detected for all end products, there were
no compounds with adjacent 13C nuclei produced from [4,5-
13C2]myo-inositol. This indicated that the cleavage of 5-dehydro-
2-deoxy-D-gluconate 6-phosphate occurred between C3 and C4,
resulting in [3-13C]propionate, [13C]CO2, and [13C]formate as
end products (Fig. 2c). The labelled ethanol and acetate might
have been produced from a conversion of intermediate labelled
acetyl-CoA formed in myo-inositol pathway (Fig. 3b). This pos-
sibility was confirmed by the results of labelled compounds
detected from cells grown in [4-13C]myo-inositol. We ran these
samples with the number of scans of 1024 to get visible peaks
(Fig. 2d, e). [13C]CO2 was found as major end product and small
quantities of [13C]formate, [2-13C]propionate, [2-13C]acetate and
[3-13C]propionate. This result not only confirms the cleavage of
5-dehydro-2-deoxy-D-gluconate 6-phosphate between C3 and C4,
forming [13C]CO2 and [13C]formate but also indicates that
dehydration of scyllo-inosose was mainly across the C4–C5 bond
with a small portion of which the dehydration was across the
C1–C6 bond (Fig. 2f). Importantly, no labelled butyrate was
detected in any condition, confirming that butyrate is not the end
product of inositol fermentation. In addition, we also grew A.
rhamnosivorans in [13C6]myo-inositol, resulting in the formation
of labelled compounds including [13C3]propionate, [13C2]acetate,
[13C]CO2, [13C]formate, [13C3]lactate, [13C2]ethanol and [2-13C]
butyrate (Supplementary Fig. 3). While all other products were
labelled in all carbon atoms, only one labelled carbon was
detected at C2 position of butyrate. The fact that labelled lactate
was formed along with labelled butyrate, supported the
Fig. 2 Elucidation of myo-inositol pathway via 13C-NMR analysis. High-resolution 13C-NMR spectra showing [4,513C2]myo-inositol fermentation products
that are [3-13C]propionate, [13C]CO2, [1-13C]ethanol, [2-13C]acetate, [1-13C]acetate, [13C]formate (b) with anticipated scheme of 13C flow (c), and [4-13C]myo-
inositol fermentation products that are [13C]CO2, [13C]formate, [2-13C]propionate, [2-13C]acetate and [3-13C]propionate (e) with anticipated scheme of 13C
flow (f). a and d show concentrations of substrate and end metabolites analysed using high performance liquid chromatography-refractive index detection
(HPLC-RI) when the cells were grown in [4,513C2]myo-inositol and [4-13C]myo-inositol respectively. Red arrows indicate the samples time points for 13C-NMR.
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explanation that the small amount of butyrate observed in the
growth experiments (Fig. 1) was derived from lactate/acetate
rather than myo-inositol. This proposed route is in line with the
detection of intermediates by liquid chromatography high-
resolution mass spectrometry (LC-MS/MS). We detected 4 key
intermediates of this pathway, including scyllo-inosose; 3,5/4-
trihydroxycyclohexane-1,2-dione; 5-dehydro-2-deoxy-D-gluco-
nate and 5-dehydro-2-deoxy-D-gluconate 6-phosphate (Supple-
mentary Fig. 4 and Supplementary Table 4). While the first three
intermediates were accumulated rapidly and subsequently uti-
lised, 5-dehydro-2-deoxy-D-gluconate 6-phosphate was only
detected in small quantities in the first 2 h and quickly consumed.
This rapid consumption may explain the inability to detect the
following intermediates, including 3-oxopropionyl-CoA and 3-
oxopropionate. Another reason might be due to their short half-
times that limit the mass spectrometry analysis. Based on the
NMR and mass spectrometry data, the entire metabolic myo-
inositol pathway was reconstructed (Fig. 3a) and further inves-
tigated by proteogenomic approach in combination with enzyme
analysis (see below).
Proteogenomic and comparative genomic analyses revealed the
presence of entire myo-inositol pathway to propionate in
Anaerostipes spp. The complete genome of A. rhamnosivorans
DSM26241T was determined by single molecule sequencing and
found to contain 3,588,860 bp with a GC content of 44.5% coding
for a total of 350 subsystems with 3556 protein-coding sequences
(CDSs) (NCBI accession number CP040058). Complete acetyl-
CoA and rhamnose degradation pathways were detected and
predicted to operate via butyryl-CoA:acetate CoA transferase (EC
2.8.3.8), the enzyme that is involved in the final step of the
butyrate synthesis pathway (Supplementary Table 2). Lactate
permease and lactate dehydrogenase were also found encoded in
the genome, which explains the capability of A. rhamnosivorans
to use lactate28. In addition, gene candidates for myo-inositol
metabolic pathway were identified in the annotated genome of A.
rhamnosivorans DSM26241 (Fig. 3a). Myo-inositol catabolism
involved multiple and stepwise reactions including 6 genes
(iolBCDEGJ) for the conversion of myo-inositol to glycerone
phosphate and 3-oxopropionate44 (Fig. 3A). Notably, 11 copies of
myo-inositol 2-dehydrogenase (iolG) and 4 copies of inosose
Fig. 3 Postulated myo-inositol metabolic pathway via proteogenomic analysis. a Differential protein abundance in myo-inositol and rhamnose. The T-test
result shows that proteins are considered to be significantly (orange dots) different between the two conditions when there is a difference of a factor 10 or
larger between the Inositol and Rhamnose condition (that is Log10 Protein abundance ratio (Inositol/Rhamnose) below −1 or above 1) and a p-value below
0.002 (−Log10 p-value > 2.7). Contaminants (human keratins and bovine trypsin), shown as grey dots, show poor p-values as expected since they should
not be significantly different (-Log10 p-values below 1.4= p > 0.04). Other proteins identified and quantified do not show a significantly different
abundance (blue circles) between the Inositol and Rhamnose condition. b myo-inositol metabolic pathway. The locus tag and fold induction of the proteins
(bold) based on the proteomic data are indicated for each reaction. Myo-inositol is first metabolised via a step-wise reaction by myo-inositol
dehydrogenase (IolG encoded by AR1Y2_0317), inosose dehydratase (IolE encoded by AR1Y2_0345), epi-inositol hydrolase (IolD encoded by
AR1Y2_1105), 5-deoxy-glucuronate isomerase (IolB encoded byAR1Y2_1106) and 5-keto-2-deoxygluconokinase (IolC encoded by AR1Y2_1104) before
being cleaved off to glycerone phosphate and 3-oxopropionate by 5-keto-2-deoxy-D-gluconate-6 phosphate aldolase (IolJ encoded by AR1Y2_1054). While
glycerone phosphate is further converted to pyruvate via glycolysis, 3-oxopropionate enters a reduction branch involved newly identified enzymes including
a 3-oxoacid CoA transferase (OxcT encoded by AR1Y2_1115), an enoyl-CoA dehydratase (AcaD encoded by AR1Y2_1116) and an acyl dehydrogenase
(EcdH encoded by AR1Y2_1117) and acyl dehydrogenase complex (AcaD-Etf encoded by AR1Y2_1050-1052). CO2/H2 or formate is also formed from a
conversion of pyruvate to acetyl-CoA involved pyruvate-flavodoxin oxidoreductase (Por encoded by AR1Y2_3042). Genes involved in a production of side
products (lactate and ethanol) are also indicated in the graph. c Homologues of myo-inositol pathway gene candidates in genomes of Anaerostipes isolates.
The similarity of each pathway gene to this of A. rhamnosivorans is indicated via colour code from yellow to blue ranging from low to high. The genes and
locus tags of the myo-inositol pathway genes in the genome of A. rhamnosivorans are shown on the right of the figure.
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dehydratase (iolE) were found in the genome, indicating the
adaptation of A. rhamnosirovans to this cyclic polyol. Energy is
predicted to be conserved via substrate level phosphorylation as
well as electron transport chain by acryloyl-CoA dehydrogenase/
Etf complex (AR1Y2_1050-1052)47. Several permeases were also
found in the genome with a putative transporter gene
(AR1Y2_1059) located closed to myo-inositol catabolic genes
(Supplementation Fig. 5). To elucidate proteins involved in the
propionate production from 3-oxopropionate, we analysed proteins
extracted from A. rhamnosivorans DSM26241T grown on either
myo-inositol or rhamnose by semi-quantitative proteomics using
mass spectrometry (Supplementary Tables 1–2 and Supplementary
data 2). The proteins predicted to be involved in myo-inositol
and rhamnose fermentation were highly abundant in the
respective proteomes (Fig. 3b). We found under rhamnose
condition, A. rhamnosivorans DSM26241T produced abun-
dantly all proteins involved in rhamnose fermentation and
employed a rhamnose pathway48 and acetyl-CoA pathway49,
forming 1,2-propanediol and butyrate as final metabolites.
Interestingly, all proteins involved in myo-inositol pathway
were not only highly abundant but also significantly induced
during growth on myo-inositol compared with rhamnose
(Fig. 3b). Enzymes involved in the six stepwise conversions of
myo-inositol to glycerone phosphate and 3-oxopropionate
were increased up to 106-fold in the proteome of myo-inosi-
tol-grown cells, including myo-inositol 2-dehydrogenase (IolG
encoded by AR1Y2_0317), inosose dehydratase (IolE encoded
by AR1Y2_0345), epi-inositol hydrolase (IolD encoded by
AR1Y2_1105), 5-deoxy-glucuronate isomerase (IolB encoded
by AR1Y2_1106), 5-keto-2-deoxygluconokinase (IolC enco-
ded by AR1Y2_1104) and 5-keto-2-deoxy-D-gluconate-6-
phosphate aldolase (IolJ encoded by AR1Y2_1054). Among
these, iolCDB (AR1Y2_1104-1106) were located in a putative
operon and they shared similar induced protein abundances in
cells grown on myo-inositol. A transcriptional repressor (IolR
encoded by AR1Y2_1091) was also found a few genes down-
stream from the iolCDB operon (Supplementary Table 1 and
Supplementary Fig. 5). Remarkably, 2 other myo-inositol 2-
dehydrogenases (IolG encoded by AR1Y2_0342 and AR1Y2_
1057) were abundantly produced in the myo-inositol condi-
tion along with a predicted inosose isomerase (IolJ encoded by
AR1Y2_1058) (Supplementary Table 1). As the myo-inositol
2-dehydrogenase and the inosose isomerase have been
reported to confer the ability to convert chiro-inositol to
scyllo-inosose, an intermediate of myo-inositol fermentation44,
the over-production of these enzymes by A. rhamnosivorans
indicates the capability of this strain to metabolise chiro-
inositol, an isomer of myo-inositol as well. We also confirmed
this ability of chiro-inositol conversion experimentally (Sup-
plementary Fig. 6). The conversions from glycerone phosphate
to acetyl-CoA were predicted as shared steps between myo-
inositol and rhamnose pathway. Hence, no remarkable dif-
ferences were found for the abundance of these proteins in
cells grown on either rhamnose or myo-inositol. In contrast,
enzymes involved in the conversion of 3-oxopropionate to
propionate were most abundant and substantially induced, up
to 6440 times, during growth on myo-inositol compared to
rhamnose. These included 3-oxoacid CoA transferase (OxcT
encoded by AR1Y2_1115), acyl-CoA dehydrogenase (AcaD
encoded by AR1Y2_1117), enoyl-CoA hydratase (EcdH
encoded by AR1Y2_1116) and acryloyl-CoA dehydrogenase/
Etf (AcaD-Etf encoded by AR1Y2_1050-1052). Interestingly,
oxcT, ecdH and acaD (AR1Y2_1115-1117) were located in a
putative operon. The 3-oxoacid CoA transferase protein
(OxcT encoded by AR1Y2_1115) was predicted to be involved
in two key reactions, one converting 3-oxopropionate to 3-
oxopropionyl-CoA and the other converting propionyl-CoA
to propionate (Fig. 3a), that explained the high (2294-fold)
induction in myo-inositol-grown cells (Fig. 3b). The sub-
stantial increase in the abundance of 3-oxoacid CoA trans-
ferase in cells grown on myo-inositol could partially explain
the absence of accumulation of either 3-oxopropionyl-CoA or
3-oxopropionate, as we were not able to detect these inter-
mediates by reversed phase LC-MS/MS (see above; the
Methods section and Supplementary Fig. 4). The acryloyl-CoA
dehydrogenase/Etf complex (AcaD-Etf encoded by
AR1Y2_1050-1052) was predicted to be involved in energy
conservation; hence its abundance was much higher in myo-
inositol grown as compared to rhamnose-grown cells (up to
6440-fold). It is predicted that the production of small
amounts of ethanol and lactate (see above) was likely needed
to prevent the excess reducing equivalence produced during
myo-inositol fermentation. Since both ethanol and lactate
production also took place during rhamnose metabolism, the
proteins involved in these reactions were not induced in
abundance and were not considered further.
To investigate how widely spread this newly discovered
pathway is in Anaerostipes spp., we compared the A. rhamno-
sivorans genome with that of the publicly available genomes of A.
caccae, A. hadrus SSC/2, A. hadrus PEL85, A. hadrus DSM3319T
and A. hadrus BPB5. The genomes of the four A. hadrus strains
were highly similar with more than 97% similarity for average
nucleotide identity (ANI) and substantially different from
genomes of A. rhamnosivorans and A. caccae with only 70%
ANI similarity (Supplementary Table 3). Homologues of myo-
inositol pathway genes were determined by blasting amino acid
sequences of gene candidates from A. rhamnosivorans on other
genomes (Fig. 3c). Intriguingly, most strains have homologues of
myo-inositol pathway genes except A. hadrus DSM3319T,
indicating the adaptation of Anaerostipes strains to substrate
availability in the intestine. These results are in line with the
growth tests in which A. rhamnosivorans, A. caccae and A. hadrus
PEL85 were able to convert myo-inositol to propionate while A.
hadrus DSM3319T was not (Fig. 1). Detailed analysis of the myo-
inositol pathway gene localisation showed that this pathway
composed of several gene clusters that were shared by all
Anaerostipes strains. The arrangement of these gene clusters was
almost identical among A. hadrus strains while that of A.
rhamnosivorans was highly similar to that of A. caccae
(Supplementary Fig. 5). Furthermore, a homologue of myo-
inositol 2-dehydrogenase (IolG) (encoded by AR1Y2_0342) was
only found in A. caccae but absent in all other strains while
homologues of the other myo-inositol 2-dehydrogenase (encoded
by AR1Y2_1057) was present in all strains. To investigate which
IolG homologue was involved in chiro-inositol conversion, we
incubated A. rhamnosivorans, A. caccae, A. hadrus DSM3319T
and A. hadrus PEL85 in chiro-inositol. Intriguingly, only A.
rhamnosivorans and A. caccae, which had the homologue of
AR1Y2_0342, were able to convert chiro-inositol to propionate
and acetate while A. hadrus DSM3319T and A. hadrus PEL85
were not (Supplementary Fig. 6). These results suggest myo-
inositol 2-dehydrogenase (IolG encoded by AR1Y2_0342) likely
conferred the ability of metabolising chiro-inositol.
A specific CoA transferase involved in propionate production.
Enzymes from CoA transferase family are known to be involved
in propionate and butyrate formation from many different sub-
strates, including sugars and amino acids49–51. A total of nine
CoA transferases were found to be encoded by the genome of A.
rhamnosivorans but only two of these were detected in the pro-
teomic analysis with high abundance and included 3-oxoacid
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CoA transferase encoded by AR1Y2_1115 and butyryl-CoA:
acetate CoA transferase encoded by AR1Y2_2204 (Fig. 3b and
Supplementary Tables 1–2). These CoA transferases and cano-
nical CoA transferases from other anaerobes were used to con-
struct a phylogenetic tree, forming five distinct clades
corresponding to five different reactions (Fig. 4a). Butyryl-CoA:
acetate CoA transferase, butyryl-CoA:4-hydroxybutyrate CoA
transferase, butyryl-CoA:acetoacetate CoA transferase and pro-
pionate CoA transferase are involved in butyrate formation from
sugars, 4-aminobutyrate/succinate, lysine and propionate forma-
tion respectively. While the protein with locus tag AR1Y2_2204
was clustered with butyryl-CoA:acetate CoA transferase from
butyrate-producing bacteria, that with locus tag AR1Y2_1115 was
found to cluster with well-studied propionate CoA transferases of
other anaerobic bacteria, including the 3-oxoacid/propionate
CoA transferases from Coprococcus catus (WP117539849);
Megasphaera elsdenii (ALG42129); Ralstonia eutropha H16
(A2718) and Clostridium propionicum (AJ276553)13,52–54. In
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addition, the abundance of the protein with locus tag
AR1Y2_2204 was only 1.7 times higher in cells grown on
rhamnose as compared to myo-inositol, suggesting this protein is
constitutively expressed. Remarkably, the protein with locus tag
AR1Y2_1115 was 2294-times more abundant in myo-inositol
than rhamnose-grown cells, indicating that 3-oxoacid CoA
transferase (OxcT encoded by AR1Y2_1115) functions as pro-
pionate CoA transferase and is actively involved in propionate
formation from myo-inositol.
To further confirm this propionate CoA transferases activity,
anaerobic cell-free extracts were prepared from cells grown on
myo-inositol and rhamnose. Subsequently, we performed anaero-
bic activity assays using propionyl-CoA or butyryl-CoA and
acetate as substrates (Fig. 4b–d). The activity was measured
indirectly via a coupling reaction with citrate synthase assay55.
While A. rhamnosivorans only produced propionate (and acetate)
from myo-inositol, butyrate was detected from rhamnose (Fig. 4c),
suggesting that two different CoA transferases were involved in
propionate and butyrate formation. The activity for propionyl-
CoA and butyryl-CoA was found in all anaerobic cell-free extracts
during the exponential phase while no activity was found in a
negative control (an enzyme extract of Intestinimonas butyrici-
producens grown on lysine and known to contain butyryl-CoA:
acetoacetate CoA transferase50). This is not surprising as CoA
transferases have been reported to have a broad substrate
specificity56. Specifically, the CoA transferase activities of the
anaerobic cell-free extracts from rhamnose-grown cells were
higher than these from myo-inositol-grown cells regardless of
substrates and growth phase, indicating two different CoA
transferases being active in two growth conditions. Additionally,
during exponential phase the ratio of CoA transferase activity for
propionyl-CoA over that of butyryl-CoA (0.52 up to 0.57) was
increased in cells grown on myo-inositol but decreased in those
grown on rhamnose (0.71 down to 0.64) (see Fig. 4d).
Furthermore, the induction of the 3-oxoacid CoA transferase
encoded by AR1Y2_1115 in the inositol condition was in
agreement with the increased propionate CoA transferase
activities along with propionate production from inositol during
exponential phase with (Fig. 4e, f). These results indicate an active
role of 3-oxoacid CoA transferase (OxcT encoded by
AR1Y2_1115) in propionate production from myo-inositol while
butyryl-CoA:acetate CoA transferase (But encoded by
AR1Y2_2204) was involved in butyrate formation from rhamnose.
Metagenomic analysis and faecal enrichment on [13C6]phytate
indicate the physiological relevance of inositol fermentation by
Anaerostipes in human gut. To further investigate the relevance
of myo-inositol metabolism in the intestinal tract, we analysed
metagenomes of 65 subjects from a healthy population char-
acterised in the Human Microbiome Project1. The results
revealed the presence of the myo-inositol pathway genes in the
vast majority (>80%) of the cohort with a relative abundance of
~0.3% of the annotated genes (Supplementary Fig. 7). In addition,
genes coding for phytases derived from Bifidobacterium spp. were
also detected in a quarter of the entire population, notably B.
longum subsp. infantis and B. pseudocatenulatum. The co-
occurrence of the myo-inositol pathway and phytase genes in
these subjects indicated the presence of a phytate food chain
involving Anaerostipes spp. in the intestinal tract. The function-
ality of such a trophic chain was demonstrated by coculturing A.
rhamnosivorans and Bifidobacterium longum subsp. infantis on a
medium containing phytate (Supplementary Fig. 8). This resulted
in the accumulation of a small but persistent amount myo-ino-
sitol in a monoculture of B. longum subsp. infantis and produc-
tion of lactate and acetate from the medium. In contrast, in the
presence of both B. longum subsp. infantis and A. rhamnosivor-
ans, no accumulation of myo-inositol was observed and instead
greater propionate formation observed. Although butyrate was
detected in the coculture of B. longum subsp. infantis and A.
rhamnosivorans, a similar amount of butyrate was already pro-
duced by A. rhamnosivorans when grown in a medium without
phytate (Supplementary Fig. 8). This implies the butyrate for-
mation was likely from the fermentation of medium components
by A. rhamnosivorans rather than phytate. These results indicate
the cross-feeding between B. longum subsp. infantis and A.
rhamnosivorans on phytate via myo-inositol interspecies-transfer,
leading to an increased propionate production.
To further support the presence of a phytate food chain in the
intestinal tract leading to propionate, we performed enrichment
studies with [13C6] phytate using faecal samples from two healthy
donors with low levels of endogenous Anaerostipes species
(Supplementary Fig. 9) and analysed the end metabolites using
[13C] NMR (see Fig. 5 and Supplementary Fig. 11). Our results
showed that microbiota of these two donors converted [13C6]
phytate into [13C]acetate and [13C]butyrate as end metabolites
(Fig. 5a). A. rhamnosivorans alone was not able to metabolise
[13C6]phytate (Supplementary Fig. 10). However, we found that
[13C]propionate was produced from [13C6]phytate once A.
rhamnosivorans cells were simultaneously added to the medium
with the faecal inoculum (Fig. 5b–d). The SCFA analysis showed
that a significant amount of propionate (together with acetate and
butyrate due to the activity of faecal microbiota) was produced
from the added phytate (Fig. 5c). These results imply that A.
rhamnosivorans metabolised the inositol released from phytate
Fig. 4 Identification of propionyl coA transferase in A. rhamnosivorans. Phylogeny of CoA transferase family (a) and CoA transferase activity (b–f).
a Phylogenetic tree of predicted CoA transferases from A rhamnosivorans DSM26241T (bold) and other anaerobes. The tree was constructed using
sequences from butyryl-CoA:acetate CoA transferase (But, in blue), butyryl-CoA:4-hydroxybutyrate CoA transferase (4Hbt, in green), butyryl-CoA:
acetoacetate CoA transferase (Ato) alpha subunit (AtoD, in orange), beta subunit (AtoA, in yellow) and oxoacid CoA transferase (OxcT, in light blue),
respectively. b Growth curves of A. rhamnosivorans on myo-inositol and rhamnose of which cells at 2 time points were harvested for crude extracts and
enzyme assays. c Butyrate and propionate production from rhamnose and myo-inositol condition at T1 and T2 (n= 2 technical replicates). Data are
presented as mean values ±SD. d Ratios between activities on propionyl-CoA out of butyryl-CoA in all anaerobic cell-free extracts with blue and purple
column for crude extracts from myo-inositol and rhamnose respectively. CoA transferase activities for butyryl-CoA and propionyl-CoA in anaerobic cell-
free cell extracts were determined and subsequently used for ratio calculation. Each measurement was performed in triplicate (n= 3 technical replicates).
Data are presented as mean values ±SD. Cell free extract of Intestinimonas butyriciproducens AF211 grown on lysine was used as a negative control (NC). As
strain AF211 did not show any activities toward either butyryl-CoA or propionyl-CoA, the ratio result of this strain was omitted from the graph to avoid
confusion. e Growth curve of A. rhamnosivorans in myo-inositol (n= 2 biological replicates). Red arrows show sampling points (T1–T5) of which enzyme
extracts were obtained for the assay. Data are presented as mean values ±SD. f Increases in enzyme activities toward propionyl-CoA during exponential
phase correspond to an increase in propionate production and inositol consumption. Data of CoA activity are presented as mean values of biological
duplicates (n= 2) and technical triplicates (n= 3) while values shown for inositol and propionate concentration are means of biological duplicates (n= 2).
Data are presented as mean values ±SD.
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degradation by gut bacteria for propionate formation, hence
forming a phytate-dependent food chain. The stable isotope
analysis of the end products clearly shows the active involvement
of A. rhamnosivorans in the phytate degradation. Similar results
of phytate enrichment were obtained with the second faecal
donor (Supplementary Fig. 11), confirming the role of A.
rhamnosivorans in propionate production from phytate. Indeed,
humans often consume phytate-containing plants, such as brans
and cereals, and hence myo-inositol is likely released by microbial
activities in the large intestine and serves as substrate for
intestinal bacteria57. Our results show that dietary phytate can be
utilised by gut bacteria, leading to the production of acetate,
propionate and butyrate that involve different types of intestinal
microbes and emphasise the key role of A. rhamnosivorans in
propionate and acetate production from inositol or its precursor
phytate.
Anaerostipes spp. as potential health promoting bacteria. A
comparative analysis of over 10,000 available NCBI genomes
showed that seven bacterial species contained the complete ino-
sitol pathway, of which five belonged to Anaerostipes spp., one to
a bacterium belonging to the Lachnospiraceae and related to
Anaerostipes, and one to a non-intestinal soil isolate
Anaerosacchriphilus polymeriproducens (Supplementary data 1).
This result suggests that Anaerostipes is a key taxonomic group,
members of which are predicted to contain the entire metabolic
pathway to convert inositol to propionate.
Recently, a comprehensive metagenomic analysis of the
intestinal microbiota in a large prediabetes/diabetes cohort was
reported58. Using this dataset we performed a deep analysis of the
genes involved in the inositol-to-propionate pathway and
observed a significant negative association of the propionate
production gene cluster but not the inositol utilisation cluster to
metabolic disease biomarkers (Fig. 6a). It has been known that
several bacteria are able to metabolise myo-inositol to acetate and
ethanol employing the inositol utilisation genes44,45 while the
propionate production gene cluster has been only observed in
Anaerostipes spp. Of interest, the relative abundance of the
propionate production gene cluster was significantly low in
individuals with high levels of fasting insulin (P= 2.6e-04) and
serum triglyceride (P= 3.0e-05) levels (Fig. 6b). In addition, a
significant negative correlation between the relative inositol
pathway abundance with fasting insulin was also observed (P=
1.1e-03) (Supplementary Fig. 12). This observation is in line with
a previous report on the association of myo-inositol pathway
genes of A. hadrus SSC/2 located on a genomic structure variant
(Supplementary Fig. 5) with lower host metabolic disease risk23.
Fig. 5 [13C6]-labelled phytate degradation by human microbiota in presence or absence of A. rhamnosivorans. a 13C compounds detected by NMR at To
or 4 day incubation in phytate enrichment using faecal microbiota. b 13C compounds detected by NMR at To or 4 day incubation in phytate enrichment
using faecal microbiota and A. rhamnosivorans. c Quantity of metabolite production analysed by high performance liquid chromatography - refractive index
detection (HPLC-RI). d A. rhamnosivorans qPCR-based cell counts at initial time points of S1 and S1 plus A. rhamnosivorans enrichments. Mean values of
technical triplicates are shown with ±SD.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25081-w ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:4798 | https://doi.org/10.1038/s41467-021-25081-w | www.nature.com/naturecommunications 9
Altogether these results indicate that propionate production from
inositol by Anaerostipes species might provide potential health
benefits.
To investigate the potential health benefit of Anaerostipes
species we studied the impact of A. rhamnosivorans and inositol
administration in mice fed a western diet (high in fat and
sucrose)59. First, we tested the usefulness of this mouse model by
determining the fate of live cells of A. rhamnosivorans when
administered via oral gavage. The results show that A.
rhamnosivorans persisted well in faecal samples of mice fed with
a western diet (Supplementary Fig. 13). In this mouse model we
subsequently administered live or heat-killed cells of A.
rhamnosivorans in the presence or absence of myo-inositol for
7 weeks. Body weight gain did not differ between treatment
groups (Supplementary Fig. 14a–b) and neither did glucose
tolerance determined after 6 weeks treatment (Supplementary
Fig. 14c–f). We noted a trend (P= 0.09) towards lower fasting
glucose after 6 weeks of treatment with live A. rhamnosivorans
compared to heat-killed bacteria (Fig. 6c) and a significant (P=
0.04) lower fasting glucose when the mice were also treated with
myo-inositol (Fig. 6d). In addition, the reduction of insulin levels
was not significant between heat-killed and live treatment groups
(Supplementary Fig. 14g–h) but we found a significant negative
correlation (P= 0.03) between the ratio of caecal propionate:
butyrate and fasting serum insulin levels for treatments of only
co-administration of myo-inositol with either live or heat-killed
A. rhamnosivorans (Fig. 6e). This suggests that microbial inositol
conversion to propionate (rather than production of butyrate
Fig. 6 Propionate production gene cluster negatively associates with metabolic risk markers in prediabetes/diabetes cohort and reduced fasting
glucose in mice fed with live A. rhamnosivorans. Metagenomic analysis (a) shows that inositol utilisation gene cluster (cluster 1) did not form significant
correlation with metabolic biomarkers while propionate production gene cluster (cluster 2) was significantly negatively associated with metabolic risk
markers, especially fasting insulin and serum triglyceride (Spearman correlation); (b) shows significant differences in levels of fasting insulin (P= 2.6e-04)
and serum triglyceride (P = 3.0e-05) in individuals with low versus high abundances of cluster 2 genes in a Swedish prediabetes cohort (Wilcox rank-sum
test). −P < 0.1; *P < 0.05; +P < 0.01; #P < 0.001. The horizontal line in each box represents the median, the top and bottom of the box the 25th and 75th
percentiles, and the whiskers 1.5 times the interquartile range. Fasting glucose levels in western diet fed C57BL/6J mice after 6 weeks oral administration of
heat-killed or live A. rhamnosivorans without (c) or with myo-inositol (d). N= 10 mice per group. Data are mean ± SEM; statistical analysis was done by
unpaired two-tailed Student’s t tests. Pearson correlation (e) between caecal propionate:butyrate ratio and fasting insulin in mice treated with heat-killed
(blue circles) or live (orange circles) A. rhamnosivorans plus myo-inositol (P= 0.03).
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from carbohydrates or lactate and acetate) may be needed to
decrease insulin sensitivity. As we did not observe a strong effect
of active treatment further investigations are required.
Discussion
In this study, we describe a propionate synthesis pathway from
myo-inositol by butyrogenic Anaerostipes species. This brings the
number of propionate synthesis pathways up to four, including
succinate, acrylate, propanediol and myo-inositol pathway. More
than half of the tested Anaerostipes strains were able to grow on
myo-inositol as the sole carbon and energy source by converting
myo-inositol to propionate, acetate, formate, CO2 and hydrogen.
The myo-inositol pathway was further elucidated in A. rhamno-
sivorans DSM26241T by determining the metabolic route of the
13C-labelled myo-inositol conversion by NMR, mass spectro-
metry combined with proteogenomic analysis and enzyme
determinations. To our knowledge, it has not been reported
elsewhere that intestinal bacteria are able to anaerobically convert
myo-inositol into propionate. The predicted pathway includes
myo-inositol catabolic genes which were to some extent similar to
these in Aerobacter aerogenes and Bacillus subtilis43–45. However,
one of the key steps of the propionate synthesis pathway that
differentiated this from previously reported routes was the con-
version of 3-oxopropionate to 3-oxopropionyl-CoA via a 3-
oxoacid CoA transferase (Fig. 3). Interestingly, this latter enzyme
based on the proteome data was predicted to be involved in
propionate formation and this has been proven via enzyme
activity assays (Fig. 4). Unlike the myo-inositol pathway in A.
rhamnosivorans DSM26241T, 3-oxopropionate was dec-
arboxylated to produce acetyl-CoA that involved a CoA-
dependent malonate-semialdehyde dehydrogenase in Bacillus
subtilis60. The further conversion of 3-oxopropionyl-CoA to
propionate is predicted to follow the reduction route and involve
acyl-CoA dehydrogenase (AcaD encoded by AR1Y2_1117),
enoyl-CoA hydratase (EcdH encoded by AR1Y2_1116), 3-
oxoacid CoA transferase (OxcT encoded by AR1Y2_1115)
acryloyl-CoA dehydrogenase and the α and β subunits of an
electron transfer flavoprotein (AcaD-Etf encoded by
AR1Y2_1050-1052) (Fig. 3a). Myo-inositol is naturally present in
animal and plant cells in either free form or as a bound-
component of phospholipids or inositol phosphate derivatives,
such as phytate. The latter dietary compounds can release myo-
inositol in the human colon via the activity of mainly microbial
phytases in the intestine61,62. Our results on [13C6] phytate
enrichment using human stool samples show that intestinal
bacteria are well capable of utilising phytate, to produce beneficial
SCFAs to the human host (Fig. 5). Our data also indicate that
phytate degradation by gut microbiota only leads to propionate
and acetate formation in presence of A. rhamnosivorans. This is
in line with the finding of a dietary intervention study where the
abundance of Anaerostipes spp. was positively associated to an
increase of faecal propionate formation in humans after a 3-
month Mediterranean diet41. We discovered this myo-inositol
pathway in Anaerostipes spp. that were previously only found to
be colonic butyrate producers, illustrating the high metabolic
flexibility of intestinal bacteria permitting quick adaptation to
changes of nutrient supply in the gut.
Although the myo-inositol pathway was found in several
Anaerostipes spp. (A. rhamnosivorans, A. caccae, A. hadrus
PEL85), some Anaerostipes strains appeared not to have the myo-
inositol pathway nor capability of fermenting myo-inositol
(Fig. 1). This suggests that inositol fermentation might be
obtained as the adaptation to substrate availability in the intes-
tine. In fact, many copies of myo-inositol 2-dehydrogenase (IolG)
detected in A. rhamnosivorans exemplified its adaptation to this
cyclic polyol. The detailed genomic analysis on Anaerostipes
genomes showed that all myo-inositol degraders shared several
gene clusters assembling the myo-inositol pathway (Supplemen-
tary Fig. 5). The gene arrangement of these clusters in the gen-
omes was identical among A. hadrus strains and slightly different
from that of A. rhamnosivorans and A. caccae, explaining the
similar growth and metabolic activities on myo-inositol between
A. rhamnosivorans and A. caccae (Fig. 1). Screening of over
10,000 NCBI genomes indicates that Anaerostipes is the key taxon
in the gut that contains strains predicted to be capable of con-
verting myo-inositol into propionate and acetate (Supplementary
data 1). In addition, the metagenomic analysis revealed that the
majority of analysed subjects carried the myo-inositol pathway
genes, which is in line with the frequent detection of Anaerostipes
in healthy humans. Moreover, we also found many subjects
carried genes for phytases, indicating the prevalence of a food
chain from dietary phytate involved Anaerostipes spp. in the gut.
Importantly, the metagenomic analysis on the prediabetes/dia-
betes cohorts showed negative correlations of the propionate
production gene cluster to metabolic disease biomarkers (Fig. 6a).
This correlation was significant for fasting insulin and serum
triglyceride in particular (Fig. 6b), indicating the potential benefit
of inositol fermentation to propionate to host metabolism. We
further investigated this by supplementation of A. rhamnosivor-
ans with or without myo-inositol in mice. We found that live A.
rhamnosivorans reduced fasting glucose as compared to heat-
killed A. rhamnosivorans after 6 weeks and the reduction of
glucose level became significant once A. rhamnosivorans was
administered with myo-inositol (Fig. 6c, d), suggesting the
observed reduction of fasting glucose level might be via active
inositol fermentation of A. rhamnosivorans. Although no differ-
ence in neither insulin level nor glucose tolerance was observed, it
has been shown that some intestinal bacteria need a much longer
treatment with a high frequency in order to get the best effect
while no effect was observed in a short treatment63. Therefore,
our results provide the first indication of potential health benefits
of A. rhamnosivorans and imply that further studies are needed to
identifying the optimal treatment frequency, duration and dosage,
as well as understanding the interactions between A. rhamnosi-
vorans and host gut microbiota. Thus, it would be interesting to
study the influence of environmental factors on the expression of
the inositol pathway in Anaerostipes spp. in the gut.
A previous study reported that the presence of a microbial
genomic structural variant of A. hadrus SSC/2 carrying myo-
inositol pathway genes (Supplementary Fig. 5) was associated
with reduced host metabolic disease risk23. In addition, a sig-
nificant decrease of Anaerostipes abundance was also observed in
type 2 diabetes patients compared to healthy subjects22. Our
detailed genomic data analysis showed that the genomes of A.
hadrus type strain DSM 3319T and A. hadrus DSM108065 do not
predict the capacity to utilise myo-inositol, which was confirmed
by our growth experiments. However, the myo-inositol pathway
was detected in genomes of other A. hadrus strains that we found
to produce propionate from myo-inositol (Fig. 1). This reportedly
also included A. hadrus SSC/2 but as this strain is not publicly
available we could not verify this experimentally. In addition, our
results indicate that the proposed effect of myo-inositol fermen-
tation is likely via the production of propionate rather than
butyrate as previously suggested23. Supplementation of the
human gut microbiome with A. rhamnosivorans may promote
propionate production via inositol or phytate, hence lowering the
risks of metabolic diseases. In fact, propionate has been proposed
to have indirect effects in diabetes via lowering lipogenesis and
serum cholesterol levels, as a result reducing the risk of diabetes
development64. As oral myo-inositol supplementation has shown
to improve insulin sensitivity in mice and human36,37,65,66, our
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25081-w ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:4798 | https://doi.org/10.1038/s41467-021-25081-w | www.nature.com/naturecommunications 11
data point out that the effect of administered myo-inositol may be
via supporting the growth of Anaerostipes spp. in the intestine,
resulting in propionate formation which is beneficial to human
host. Although there are active myo-inositol transporters in the
small intestine, myo-inositol uptake can be inhibited by relatively
high mono-sugar load at this site67, funneling leftover myo-ino-
sitol to the large intestine as substrate for bacterial fermentation.
Besides, the combined supplementation of chiro- and myo-ino-
sitol has shown to have reduced the risk of metabolic disease
compared to that of myo-inositol treatment alone68. It is con-
ceivable that the greater effect of the combined treatment was due
to the enhanced growth of A. rhamnosivorans thanks to its cap-
ability of metabolising both isomers. Altogether our strong
metagenomic association data with the observed modest in vivo
effects suggest the co-administration of both myo-inositol and A.
rhamnosivorans as a potential therapeutic approach to improve
host health but further investigations on optimal dosage, treat-
ment duration and treatment frequency are needed.
Methods
Bacterial strains and growth media. Anaerostipes rhamnosivorans 1y-2T was
isolated by us previously and is available as DSM26241T. Anaerostipes caccae
DSM14662T, Anaerostipes hadrus DSM3319T, Anaerostipes hadrus DSM108065
and Anaerostipes butyraticus DSM 22094T were obtained from German Collection
of Microorganisms and Cell Cultures (DSMZ, Brunswick, Germany). Anaerostipes
hadrus strain PEL85 was kindly provided by Dr Ulla Hynonen of the University of
Helsinki, Finland.
All bacterial strains were routinely maintained in a modified YCFA medium
supplemented with glucose. YCFA medium composed of (g/l): 10 yeast extract,
10 soy peptone, 4 sodium bicarbonate, 2,7 sodium acetate, 4,5 monopotassium
phosphate, 0.9 dipotassium phosphate, 0.9 ammonium chloride, 0.9 sodium
chloride, 0.09 magnesium sulfate, 0.0005 resazurin, 0.5 cysteine and 1 ml of vitamin
mixture69. The vitamin mixture (per 100 ml) contains 1 mg biotin, 1 mg cobalamin,
3 mg 4-aminobenzoic acid, 5 mg folic acid and 15 mg pyridoxamine.
The growth experiments were performed in triplicate in 20 ml bicarbonate-
buffered CP medium50 supplemented with 20 mM myo-inositol or 10 mM chiro-
inositol in a 50 ml anaerobic serum bottle filled with N2/CO2 (80:20, v/v) gas in the
head phase. The inositol isomers were filter sterilised as stock solutions of 0.5 M.
The condition in which the bacteria were added to 20 ml bicarbonate-buffered CP
medium without substrate was used as control. The growth was monitored via
metabolite formation by HPLC and optical density measurement by a
spectrophotometer at a wavelength of 600 nm. To test the influence of acetate on
inositol fermentation, the bacteria were grown in a CP medium with an addition of
either 20 mM myo-inositol or 20 mM myo-inositol plus 20 mM acetate.
The coculture experiment between Bifidobacterium longum subsp. infantis
DSM20088 and A. rhamnosivorans was performed in 20 ml YCFA medium
supplemented with 20 mM sodium phytate (SIGMA). Sodium phytate was filter
sterilised as stock solution of 0.5 M. The metabolite formation was analysed by
HPLC. The monocultures of B. longum subsp. infantis and A. rhamnosivorans in
the same medium were used as control. The experiment was performed in
duplicate.
Analytical methods. Myo-inositol, chiro-inositol, glucose, rhamnose and short-
chain fatty acids and alcohols were quantified on a Thermo Scientific Spectra
HPLC system equipped with a Agilent Metacarb 67 H 300 × 6.5 mm column. The
column was kept at 45 °C while running with 0.005 M H2SO4 as eluent under a
flow of 1 ml/min. The detector was a refractive index detector. All analyses were
performed in duplicate.
Mass spectrometry. Metabolic pathways and inositol intermediates formation
were confirmed by liquid chromatography high-resolution tandem mass spectro-
metry experiments (LC-MS/MS): 10 mM inositol was added to two grown cultures
of A. rhamnosivorans from sterile 1 M stock solution then bacteria were harvested
at 30 min, and 1, 2, 3, 4 and 24 h. Metabolite production was stopped upon protein
precipitation through the addition of a mixture of acetonitrile /methanol/ water
(40/40/20, v/v/v); 10 ml of samples were filtered and sterilised through 0.2 µm
syringe filters and the eluate collected for analysis. Data were acquired using a LTQ
Orbitrap XL interfaced to an Ultimate 3000 RS (Thermo Fisher Scientific, Bremen,
Germany). Tentative identification of A. rhamnosivorans inositol metabolites was
achieved after two complementary trials: (I) reversed phase positive ion untargeted
data dependent scanning mode for the identification of organic acid coenzyme A
adducts; (II) hydrophilic interaction in targeted data dependent negative ions mode
for polyalcohol intermediates.
The first setup included the use of a thermostated (35 °C) mixed-mode
stationary reversed phase with positive charge surface (Luna Omega PS C18, 100
×2.1, 2.6 µm, Phenomenex, Torrance, CA) to improve the ionic interaction of
organic acids- coenzyme A analytes. Mobile phases (flow 0.2 ml/min) consisted in
0.1% formic acid in water (solvent A) and 0.1% formic acid in methanol (solvent
B). Samples (5 µl) were injected without any further dilution and analytes separated
through the following gradient of solvent B (minutes/%B): (0/10), (2/10), (7.5/80),
(9.5/80), while ESI interface parameters were the following: spray voltage 5.0 kV,
capillary voltage 15.0 V, capillary temperature 300 °C, e sheath gas flow and
auxiliary gas flow were 30 and 5 arbitrary units, respectively. Profile data type were
acquired in full scan Fourier transformed high-resolution (FTMS) mode in the
mass scanning range 120–900m/z. For data dependent scanning mode, MS/MS
normalised collision energy was set to 35, activation Q 0.25, activation time 25 ms,
with a 1m/z isolation window, while a reject mass list was generated by injecting
blank samples.
The second setup was based on the use of a silica sulfobetaine zwitterionic
modified HILIC column (100 ×2.1 mm, 1.7 µm, Thermo Fisher) at 35 °C. Mobile
phases consisted in 0.1% formic acid in acetonitrile (solvent A) and 0.1% formic
acid in water (solvent B). Undiluted samples were separated through the following
gradient of solvent B (minutes/%B): (0/10), (2.5/10), (8.5/85), (10/85) at a flow rate
of 0.2 ml/min and the injection volume was 5 µl. The current ion of potential
candidates was scanned in the m/z range of 60–300 in negative mode and the ion
source parameters were the following: spray voltage −4.5 kV, capillary voltage
−25.0 V70, sheath gas and auxiliary gas were 25 and 10 arbitrary units, respectively.
Target analytes listed in Supplementary Table 4 were scanned in FTMS and MS/
MS experiments by using CID fragmentation with a normalised collision energy set
to 30; wherever target analytes were not detected, for data dependent scanning
mode, MS/MS normalised collision energy was set to 35, activation Q 0.25,
activation time 25 ms, with a 1m/z isolation window, while a reject mass list was
generated by injecting blank samples. Analyte responses were monitored by using
Xcalibur 2.1 (Thermo Fisher Scientific, Bremen). While target analytes chemical
composition, high-resolution spectra and tandem mass spectra were compared
with reference compounds present in publicly available databases as Human
Metabolome Database (https://hmdb.ca/) and KEEG (https://www.kegg.jp/) and
the reliability of the spectral assignment to the metabolite was achieved according
to Metabolomics Standards Initiative (MSI) level70
Nuclear magnetic resonance. A. rhamnosivorans strain 1y-2T was cultivated in a
bicarbonate-buffered medium containing 10 mM of [13C6]myo-inositol, 7 mM of
[4-13C]myo-inositol or 7 mM of [4,5-13C2]myo-inositol. The growth conditions
were as described above. 13C-labelled myo-inositol and 13C-labelled phytate were
synthesised and purified as previously reported71. Samples were taken during the
growth phase at several timepoints and centrifuged at 10,000×g. Supernatants were
amended with 0.5 ml D2O (50 μl, 99.9 atom%, Sigma Aldrich) and subsequently
transferred in NMR tubes (Campro Scientific). 13C-NMR spectra were recorded at
a Bruker Avance 600 III HD spectrometer equipped with a PA BBO 600S3 BB-H-
D-05-Z NMR probe, operating at 600MHz (14T) at MAGNEtic resonance
research FacilitY (MAGNEFY, Wageningen University and Research, the Neth-
erlands). To achieve an optimal signal to noise ratio, a total of 256 scans were
recorded for all samples, except for the samples containing 7 mM of [4-13C]myo-
inositol that were measured with a total of 1024 scans due to low concentrations of
labelled products. Supernatants collected from faecal enrichments on [13C6]phytate
in the presence and absence of A. rhamnosivorans were analysed using the same
setting as described above. Chemical shifts are expressed in ppm. The peak
assignment was performed by running the pure compounds of [13C6]phytate, [13C]
myo-inositol, [1-13C]propionate, [2,3-13C2]propionate, [1-13C]acetate, [13C]CO2,
[2-13C]butyrate and these were also compared to these in Biological Magnetic
Resonance Data bank (http://www.bmrb.wisc.edu/metabolomics/
metabolomics_standards).
Phytate degradation by gut bacteria. Fresh stools were collected from two
healthy donors of whom informed consents were obtained following Good Clinical
Practice. We have complied with all relevant ethical regulations for work with
human participants. The stools were freshly diluted in anaerobic PBS before being
used as inoculum in a bicarbonate medium containing ~7 mM 13C-phytate as sole
substrate either supplemented without or with A. rhamnosivorans (2% inoculum).
Bicarbonate-buffered medium containing only [13C6]phytate or [13C6]phytate with
A. rhamnosivorans were used as controls. The samples were taken after inoculation
and 4 days incubation. The supernatants of these samples were used for 13C-NMR
analysis to monitor substrate consumption as well as HPLC analysis for metabolite
production while the pellets were harvested for gDNA extraction and followed by
quantitative PCR for A. rhamnosivorans cell counts. As the 16S rRNA sequence of
A. rhamnosivorans is highly similar to that of A. caccae28, qPCR primers for A.
rhamnosivorans were designed to have two nucleotides different from that of A.
caccae72, allowing the primers to amplify 16S rRNA sequence of A. rhamnosivorans
but not that of A.caccae and the rest. The primers were validated and optimised
using gDNA of A. rhamnosivorans and A. caccae. Primers were A.rham_F: 5′-
CTGCACTCTAGCATTACAGT-3′ and A.rham_R: 5′-GCGTAGGTGGCATGAT
AAGT-3′, which resulted in a 83 bp amplicon. The 16S rRNA gene of A. rham-
nosivorans was used to optimise temperature and make standard curves. The qPCR
programme was 95 °C for 5 min and 35 cycles consisting of 95 °C for 30 s, 60 °C for
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10 s and 72 °C for 40 s; 95 °C for 1 min and 60 °C for 1 min. DNA copies were
calculated based on standard curves.
DNA extraction, sequencing and annotation. The extraction of genomic DNA of
A. rhamnosivorans DSM26241T was performed using the MasterPure Gram-
positive DNA purification kit (Epicentre) according to manufacturer’s instructions.
The quality of the extracted DNA was measured using a NanoDrop 2000 spec-
trophotometer (Thermo Scientific, USA). The genome was sequenced using a
PacBio RSII instrument, and the data processing and filtering was done with
PacBio SMRT analysis pipeline v2.2 and the Hierarchical Genome Assembly
Process (HGAP) protocol (http://www.pacb.com/devnet/). The genome annotation
was obtained by running the assembly on RAST server73. The function of proteins
was predicted and verified manually by BLASTing the amino acid sequences in
Pfam74, InterPro75, Brenda, Uniprot databases. The annotated genome of A.
rhamnosivorans strain DSM26241T was deposited on NCBI under accession
number (GCA_005280655.1).
Genomic and metagenomic analysis. Genomes of Anaerostipes caccae DSM
14662T (GCA_000154305.1), Anaerostipes hadrus DSM3319T (GCA_000332875.2),
Anaerostipes hadrus strain BPB5 (NZ_CP012098), Anaerostipes hadrus SSC/2
(GCA_001998765.1) and Anaerostipes hadrus strain PEL85 (JYFK01000000) were
retrieved from NCBI database. The homologues of inositol pathway were identified
by blasting amino acid sequences of these proteins from A. rhamnosivorans strain
1y-2T on the genomes of other strains. The heatmap was made with seaborn python.
Pairwise genome comparison was done on JSpeciesWS server76.
Pre-quality filtered metagenomic reads obtained from stool of 65 Human
Microbiome Project subjects were downloaded from RAST using its API. These
subjects have been reported in previous study50. After converting reads to fasta
format read alignment against the pathway proteins was performed with Diamond
(v0.9.22) using a cut-off e-value of -e 0.000000001. Heatmap was made with
Python3.8.2, the Seaborn library and Inkscape. Pathway abundance was calculated
as #reads-pathway/((#reads-total × length-pathway-bp)/(4 × 106 bp))51. Kraken2
(2.0.9-beta) was used for taxonomic read classification in the metagenomic
samples77. Kraken2 classification was run with – minimum-hit-groups of 2 and –
report. The Kraken2 database used was built in July 2020 comprising of the
complete genomes in RefSeq for the bacterial, archaeal and viral domains, along
with the human genome and a collection of known vectors (UniVec_Core).
Abundance estimation of the genus Anaerostipes (taxonomy ID 207244) was
determined by Bracken (v2.5)78. The Bracken kmer distribution was built using the
previous mentioned Kraken2 database with a kmer size of 35 and ideal read length
of 350. Ideal read length was based on the median read length in all the
metagenomic samples. The script est_abundance.py from Bracken was run with the
previous mentioned kmer distribution, minimum read threshold of 1 and the
Kraken2 report file.
Proteomics. A. rhamnosivorans was grown in two conditions including YCFA
supplemented with 40 mM rhamnose or 40 mM myo-inositol. The experiments
were performed in four replicates. The bacteria were harvested during exponential
phase. The protein abundances in cultures growing with two different substrates
were examined with liquid chromatography–mass spectrometry/mass spectrometry
(LC-MS/MS). A. rhamnosivorans was grown in 4 replicates in 100 ml bicarbonate-
buffered medium containing with 40 mM myo-inositol or 40 mM rhamnose as
carbon and energy sources. Cells were collected in the exponential phase by cen-
trifugation at 4700 × g at 4 °C for 20 min. Cell pellets were washed twice and
suspended in 0.5 ml of 100 mM Tris-HCl (pH 8) and subsequently disrupted by 5-
min sonication for 1 s and 2 s pause in between while cooling on ice in a Branson
sonicator with amplitude of 50%. These suspensions were then centrifuged at
10,000 × g at 4 °C for 10 min to remove cell debris. The supernatants were reduced
with 15 mM dithiothreitol and proteins were unfolded with 6M urea and alkylated
in 20 mM acrylamide before being washed twice with 50 mM ammonium bicar-
bonate by centrifugation of the buffer and reactants through a Nanosep 3K Omega
filter (Pall) at 13500 × g for 30 min. Proteins were digested by addition of 0.5 µg
sequencing grade trypsin in 100 µl of 50 mM ammonium bicarbonate and over-
night incubation at room temperature. Peptides were acidified with 10% trifluoro-
acetic acid to pH 3 and centrifuged through the membrane. After the digestion, the
samples were kept at −20 °C upon the analysis. The samples were analysed by
injecting 18 µl sample over an analytical column 0.10 × 250 mm ReproSil-Pur 120
C18-AQ 1.9 µm beads (prepared in-house), with an acetonitrile gradient at a flow
of 0.5 µl/min on a Thermo EASY nanoLC1000 (Thermo). The gradient consisted of
an increase from 9 to 34% acetonitrile in water with 0.1% formic acid in 50 min
followed by a fast increase in the percentage acetonitrile to 80% (with 20% water
and 0.1% formic acid in both the acetonitrile and the water) in 3 min as a column-
cleaning step. An electrospray potential of 3.5 kV was applied directly to the eluent
via a stainless steel needle fitted into the waste line of the micro cross. Full scan
positive mode FTMS spectra were measured between m/z 380 and 1400 on a Q-
Exactive HFX (Thermo electron, San Jose, CA, USA) at resolution of 60,000. HCD
MS/MS fragmentation scans of the 25 most abundant 2–5+ charged peaks in the
MS scan were recorded in data dependent mode.
LC-MS/MS runs with all MS/MS spectra obtained were analysed with
MaxQuant 1.6.3.479 using the “Specific Trypsin/P” Digestion mode with maximally
2 missed cleavages and further default settings for the Andromeda search engine
except that Propionamide (C) was set as a fixed modification and variable
modifications were set for de-amidation of N and Q, Protein N-terminal
Acetylation and M oxidation80. A. rhamnosivorans database from NCBI
(GCA_005280655.1) was used together with a contaminants database that contains
sequences of common contaminants. The “label-free quantification” and the
“match between runs” options were enabled. We used de-amidated peptides for
protein quantification and all other quantification settings were kept default.
Filtering and further bioinformatic analysis of the MaxQuant/Andromeda
workflow output and the analysis of the abundances of the identified proteins were
performed with the Perseus 1.6.2.1 module (available at the MaxQuant suite).
Peptides and proteins with a false discovery rate (FDR) of <1% and proteins with at
least two identified peptides of which at least one should be unique and at least one
should be unmodified were accepted. Reversed hits were deleted from the
MaxQuant result table as well as all results showing a normalised label-free
quantitation intensity (LFQ) value of 0 for all inositol and rhamnose injections.
The normal logarithm was taken from protein LFQ MS1 intensities as obtained
from MaxQuant. Zero “Log LFQ” values were replaced by a value of 5.9 (a value
slightly lower than the lowest measured value) to make sensible ratio calculations
possible. Relative protein quantitation of inositol-grown to rhamnose-grown cells
was done with Perseus by applying a two sample Ttest using the “LFQ intensity”
columns obtained with FDR set to 0.05 and S0 set to 1. nLC-MS/MS system quality
was checked with PTXQC81 using the MaxQuant result files.
Phylogenetic tree construction. A CoA transferase phylogenetic tree was con-
structed from butyryl-CoA:acetate CoA transferases (but), butyryl-CoA:4-hydro-
xybutyrate CoA transferases (4Hbt), butyryl-CoA:acetoacetate CoA transferase
(Ato_B), butyryl-CoA:acetoacetate CoA transferase (Ato_A) from known intestinal
butyrate-producing species that were retrieved from the NCBI database (Fig. 4). 3-
oxoacid/propionate CoA transferases from Coprococcus catus (WP117539849);
Megasphaera elsdenii (ALG42129); propionate CoA transferase from Ralstonia
eutropha H16 (A2718)53 and Clostridium propionicum_Propionate_CoA trans-
ferase (AJ276553)52 were retrieved from NCBI and included in the tree. Amino-
acid sequences of butyryl-CoA:acetate CoA transferase and 3-oxoacid CoA
transferase from strain A. rhamnosivorans 1y-2T were aligned with retrieved
sequences using the CLUSTAL_X programme. A phylogenetic tree was constructed
using the neighbour-joining algorithm by the MEGA 7 with 1000 bootstraps to
obtain confidence levels for the branches.
Preparation of cell free extracts. A. rhamnosivorans was grown in 10 ml anae-
robic bicarbonate-buffered CP medium containing 20 mM rhamnose or 20 mM
myo-inositol as carbon and energy sources. Cells of Intestinimonas butyr-
iciproducens AF21150 grown in 20 ml anaerobic bicarbonate-buffered CP medium
containing 20 mM lysine were used as a negative control of the enzyme assay. Cells
were collected at early and late exponential phase by centrifugation at 10,000×g at
room temperature for 10 min. Cell pellets were washed twice in an anaerobic buffer
containing 100 mM Tris-HCl (pH 8) and suspended in 0.5 ml of the same buffer.
Cells were disrupted by repeated (5 times) sonication for 30 s and 30 s pause in
between while cooling on ice in a Branson sonicator with amplitude of 50%.
Finally, the suspension was centrifuged for 10 min at 10,000×g. The cell-free
extracts were transferred to 5 ml serum bottles sealed with rubber stopper in the
anaerobic chamber for subsequent enzyme assays. All steps were performed in an
anaerobic chamber with a N2/H2 (96:4, v/v) atmosphere, circulated over a palla-
dium catalyst to eliminate traces of oxygen. To study the activity of 3-oxoacid CoA
transferase toward propionyl-CoA during exponential phase, A. rhamnosivorans
was grown in myo-inositol and cells were harvested every hour for obtaining cell-
free extracts. Subsequent processing steps were followed as described above. This
experiment was performed in duplicate.
Detection of CoA transferase activity. CoA transferase activity in crude enzyme
extracts was determined using a spectrophotometric assay55. In the assay, acetyl-
CoA formed from CoA derivatives and acetate was condensed with oxaloacetate,
thus releasing CoA which reacted with 5,5′-dithiobis(2-nitrobenzoate) to make a
yellow thiophenolate anion. The reaction mixture (1 ml) contained 100 mM Tris-
Cl (pH 8), 200 mM acetate, 1 mM oxaloacetate, 0.15 U citrate synthase, 1 mM 5,5′-
dithiobis(2-nitrobenzoate) and either 20 μM butyryl-CoA or 20 μM propionyl-
CoA. The reaction was performed in an anaerobic cuvette with N2 in the head
space, kept at 25 °C. The formation of acetyl-CoA from butyryl-CoA or propionyl-
CoA and acetate was based on the measurement of the yellow anion at 412 nm
(ε= 13.6 mM−1 cm−1), which is produced via the coupling reaction. The activities
were expressed as Umg−1 of total proteins (U= μmol min−1). The comparative
enzyme assay between inositol and rhamnose conditions was replicated in a bio-
logical replicate, while the activity assay using extracts of cells grown in myo-
inositol during exponential phase were also replicated in a biological duplicate with
at least three technical replicates. Total protein concentration in the crude enzyme
extracts was measured using Bradford assay according to the manufacturer’s
instructions (Pierce).
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Metagenomic analysis in prediabetic/diabetic cohorts and pathway screen-
ing. BlastKOALA tool82 was used to obtain the KEGG ortholog (KO) annotation
for the two clusters of genes involved in metabolism of myo-inositol to propionate.
The MEDUSA pipeline was then used for mapping the reads to those genes
assigned to the aforementioned KOs in the IGT gene catalogue58 to obtain the KO
relative abundance table. The KO relative abundances were then associated with
measured clinical biomarkers based on Spearman correlation analysis. BLASTP
searches against the NCBI reference genomes83 using query sequences identified
from A. rhamnosivorans were performed for screening bacteria bearing the whole
myo-inositol metabolism pathway. The following BLASTP search settings with
sequence identity ≥50, query sequence coverage ≥70%, and E-value ≤ 1e-5 were
used except for ‘3-oxoacid CoA transferase’; notice that only alignments with
identity ≥70 were kept for this protein since several other highly homologues
proteins were known. Because inositol utilisation gene cluster (cluster 1) genes in
general have much broader bacterial distribution than cluster 2 genes, only species
containing at least the entire propionate production gene cluster (cluster 2) were
shown in the final list.
Animal studies. All animal experiments were done in male C57Bl/6J mice (JAX™
Mice Strain, Charles River Laboratories, Germany). Mice were housed in indivi-
dually ventilated cages (Green line Sealsafe plus, Tecniplast, Buguggiate, Italy) with
a maximum of five mice per cage. Mice were kept under constant temperature
(19–21 °C); humidity of 40–70% and a 12-h light/dark cycle with free access to
food and water. All animal experiments were conducted in accordance with the
principles of the ‘Guide to the Care and Use of Experimental Animals’ were
approved by the Ethics Committee on Animal Care and Use in Gothenburg,
Sweden. We have complied with all relevant ethical regulations for animal testing
and research.
To ensure colonisation of A. rhamnosivorans independent of diet, mice were fed
either autoclaved chow diet (5021, LabDiet, St. Louis, MO) or irradiated western
diet (WD; 41% kcal fat, 41% kcal carbohydrates TD.09683, Envigo). At the same
time the mice were fed WD (n= 5 mice) or kept on chow diet (n= 3 mice), the
mice were given 200 μl gavage of comprising 109 CFU of Live A. rhamnosivorans in
10% glycerol stock three times during 1 week. Colonisation was examined in caecal
samples collected 3 days after the last gavage.
To test if oral administration of A. rhamnosivorans could affect glucose metabolism
and body weight in WD fed mice, mice were gavaged three times per week during
seven weeks with either 0.2ml of 109 CFU of Live A. rhamnosivorans in 10% glycerol
stock (n= 10 mice) or 0.2ml of heat-killed A. rhamnosivorans (n= 10 mice). To
investigate if combination of A. rhamnosivorans and myo-inositol could have a
synergistic effect, myo-inositol (0.1mg/g body weight) was added to the bacterial
suspensions of live (n= 10 mice) and heat-killed (n= 10 mice) A. rhamnosivorans at
the same dose regimen as described above. Mice were weighed every week. An oral
glucose-tolerance test (2 g/kg body weight) was done after 6 weeks of treatment. Mice
were fasted for 5 h and blood glucose was measured from tail blood samples at t= 0,
15, 30, 60, 90 and 120-min after glucose gavage. Tail blood was also collected for
insulin analysis (at t=−30 min, 15 min and 30min) and analysed with the Ultra-
Sensitive Mouse Insulin ELISA kit (Crystal Chem, Downers Grove, IL, USA) according
to the manufacturer’s protocol. After 7 weeks of treatment, mice were fasted for 5 h
and blood and tissues were harvested. Caecum short-chain fatty acids were measured
using gas chromatography coupled to mass spectrometry detection (GC-MS). Briefly,
~20–50mg of caecum content were mixed with internal standards (16mM acetate, 3.2
mM propionate and 3.7mM butyrate), added to glass vials and freeze dried. All
samples were then acidified with 50 μl of 37% HCl, and SCFAs were extracted with two
rounds of diethyl ether extraction (2ml diethyl ether, rotation shake for 15min, and
centrifugation for 5min at 2,000×g). The organic supernatant was collected; 50 μl of
the derivatization agent N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide (Sigma-
Aldrich) was added and samples were incubated at room temperature overnight.
SCFAs were quantified with a gas chromatograph (Agilent Technologies 7890A)
coupled to a mass spectrometer (Agilent Technologies 5975C). Short-chain fatty acid
standards were attained from Sigma-Aldrich (Stockholm, Sweden).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The whole-genome sequence of A. rhamnosivorans DSM26241T has been deposited in
NCBI under the BioProject accession number PRJNA540423 and SRA accession number
CP040058. The raw mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE repository with the dataset identifier
PXD021084. The entire proteome is provided in the Supplementary information/source
data file. Metagenomes of Swedish Impaired Glucose Tolerance (IGT) cohort were used
for pathway analyses (https://doi.org/10.1016/j.cmet.2020.06.011). The clinical data are
available under restricted access for ethical and legal considerations, access can be
obtained following the standard application to the data committee. Other associated data
generated in this study are provided in the Supplementary Information/Source Data file.
The raw metagenomics data used in this study are available in the China NGDC Genome
Sequence Archive under accession code HRA000020. Used databases are biological
Magnetic Resonance Data bank (http://www.bmrb.wisc.edu/metabolomics/
metabolomics_standards); Pfam (http://pfam.xfam.org/), InterPro (https://www.ebi.ac.
uk/interpro/), Brenda (https://www.brenda-enzymes.org/), Uniprot (https://www.
uniprot.org/); NCBI genome (https://www.ncbi.nlm.nih.gov/genome/). Human
Metabolome Database (https://hmdb.ca/), KEGG (https://www.genome.jp/kegg/
compound/). Source data are provided with this paper.
Code availability
A custom code for metagenomic analyses has been deposited in github (https://gitlab.
com/bartn/inositol) and a doi (https://doi.org/10.5281/zenodo.5062693)
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